Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.

Lynda M. Vrooman,Traci M. Blonquist,Jeffrey G. Supko,Sarah K. Hunt,Jane E. O’Brien,Samantha Kay-Green,Uma H. Athale,Luis A. Clavell,Peter D. Cole,Marian H. Harris,Kara M. Kelly,Caroline Laverdière,Jean-Marie Leclerc,Bruno Michon,Jennifer Jg Welch,Kristen E. Stevenson,Donna Neuberg,Stephen E. Sallan,Lewis B. Silverman

Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.

2019

Lynda M. Vrooman
Traci M. Blonquist
Jeffrey G. Supko
Sarah K. Hunt
Jane E. O’Brien
Samantha Kay-Green
Uma H. Athale
Luis A. Clavell
Peter D. Cole
Marian H. Harris
Kara M. Kelly
Caroline Laverdière
Jean-Marie Leclerc
Bruno Michon
Jennifer Jg Welch
Kristen E. Stevenson
Donna Neuberg
Stephen E. Sallan
Lewis B. Silverman

10006Background: DFCI ALL Consortium Protocol 11-001 assessed the efficacy and toxicity of Calaspargase pegol (SC-PEG), a novel pegylated asparaginase (ASP) formulation with longer half-life, compa...

Keywords:

Lymphoma
Oncology
Pegaspargase
Pathology
Toxicity
Calaspargase pegol
Medicine
Childhood Acute Lymphoblastic Leukemia
Internal medicine
Pegylated asparaginase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations